ライフサイエンスコーパス: major depressive disorder

1 racy in prediction of treatment response for major depressive disorder.

2 broad phenotype from depressive symptoms to major depressive disorder.

3 lammation contributes to the pathogenesis of major depressive disorder.

4 le stress (CUS), a widely accepted model for major depressive disorder.

5 imal models of depression and in humans with major depressive disorder.

6 ed as a node in the dysfunctional network of major depressive disorder.

7 rgic and glutamatergic deficit hypotheses of major depressive disorder.

8 iently to several consecutive treatments for major depressive disorder.

9 s mediated by p11, a protein associated with major depressive disorder.

10 rget patient population includes adults with major depressive disorder.

11 hip between dosage and treatment response in major depressive disorder.

12 construct, face, and predictive validity for major depressive disorder.

13 s of SSRIs appear slightly more effective in major depressive disorder.

14 termediate in bipolar disorder, and least in major depressive disorder.

15 a continuum between depressive symptoms and major depressive disorder.

16 a viable strategy for preventing relapse in major depressive disorder.

17 ncluding schizophrenia, bipolar disorder and major depressive disorder.

18 e efficacy of SSRIs for treating adults with major depressive disorder.

19 xed features) are common in individuals with major depressive disorder.

20 ssants might be efficacious in patients with major depressive disorder.

21 n the efficacy and tolerability of SSRIs for major depressive disorder.

22 0.92; 1.44) to 1.40 (95% CI: 1.03; 1.90) for major depressive disorder.

23 ht the need to identify novel treatments for major depressive disorder.

24 3 adults aged 60 years or older with current major depressive disorder.

25 pted reward processing, is a core symptom of major depressive disorder.

26 s of inflammation are frequently reported in major depressive disorder.

27 s predictive of threats and is overactive in major depressive disorder.

28 g win events the striatum was underactive in major depressive disorder.

29 decreased glutamate levels in patients with major depressive disorder.

30 esis offer novel strategies for treatment of major depressive disorder.

31 gnificant suicidal ideation in patients with major depressive disorder.

32 or evaluating anti-inflammatory therapies in major depressive disorder.

33 sent a potential target for the treatment of major depressive disorder.

34 at mirror stress-associated diseases such as major depressive disorder.

35 ng antidepressant responses in patients with major depressive disorder.

36 ribute to risk of inflammatory disorders and major depressive disorder.

37 ersion, schizophrenia, bipolar disorder, and major depressive disorder.

38 tress-induced behavioral disorders including major depressive disorder.

39 gn chronopharmacological strategies to treat major depressive disorder.

40 t rare in subjects with bipolar disorder and major depressive disorder.

41 rain resting-state fMRI data from a study of major depressive disorder.

42 modest evidence of overlap with bipolar and major depressive disorder.

43 ic disorders, including autism, anxiety, and major depressive disorders.

44 pment of innovative antidepressants to treat major depressive disorders.

45 Of the 193 children, 90 had a diagnosis of major depressive disorder; 116 children had 3 full waves

46 f those participants (healthy controls = 17, major depressive disorder = 19, and bipolar disorder = 1

47 nitive control task (healthy controls = 150, major depressive disorder = 260, bipolar disorder = 202;

48 Major depressive disorder, a complex neuropsychiatric co

49 Less than half of patients suffering from major depressive disorder, a leading cause of disability

50 Major depressive disorder affects around 16 per cent of

51 ation antidepressants to treat patients with major depressive disorder after discussing treatment eff

52 factors predictive of treatment outcomes in major depressive disorder among treatment-naive adults.

53 ve a full clinical response in patients with major depressive disorder, an illness associated with dy

54 pression is reported, with 421 patients with major depressive disorder and 488 control subjects.

55 d clinical trial, adults (N=80) with current major depressive disorder and a score >/=4 on the Scale

56 0 adults age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on

57 idely throughout the body and is involved in major depressive disorder and antidepressant response.

58 sifier does not distinguish individuals with major depressive disorder and attention-deficit hyperact

59 Major depressive disorder and bipolar disorder share sym

60 nt a promising intermediate phenotype across major depressive disorder and bipolar disorder.

61 les of suicide victims who had suffered from major depressive disorder and control subjects who had d

62 Lifetime major depressive disorder and depressive symptom scores

63 e of genome-level pleiotropy between CAD and major depressive disorder and for an association with si

64 in a sample comprising 596 participants with major depressive disorder and healthy controls.

65 rted to be an efficacious antidepressant for major depressive disorder and posttraumatic stress disor

66 risk factors for psychiatric illnesses like major depressive disorder and posttraumatic stress disor

67 tive ability, neuroticism, bipolar disorder, major depressive disorder and schizophrenia (standardise

68 d depression symptoms and prior diagnosis of major depressive disorder and the trajectory of gray mat

69 sk with schizophrenia, bipolar disorder, and major depressive disorder and to identify risk loci for

70 approach in reducing the risk of relapse in major depressive disorder and to place these findings in

71 Fragile X syndrome, Rett syndrome, epilepsy, major depressive disorder, and autism spectrum disorder.

72 For women, anxiety disorders, major depressive disorder, and dysthymia were the most c

73 iatric disorders including bipolar disorder, major depressive disorder, and schizophrenia, all marked

74 and subjects with SZ, bipolar disorder, and major depressive disorder, and the messenger RNA was sub

75 ned significant after adjusting for comorbid major depressive disorder, anxiety disorder, and substan

76 on the occurrence of the following outcomes: major depressive disorder, anxiety disorder, smoking and

77 For men in both China and India, major depressive disorder, anxiety disorders, and alcoho

78 cal treatments for adolescents with unipolar major depressive disorder are associated with diagnostic

79 ions for the application of psychotherapy in major depressive disorder are discussed, with special re

80 which primarily include bipolar disorder and major depressive disorder, are the leading cause of disa

81 later, in keeping with growing evidence for major depressive disorder as an early marker of cerebral

82 Secondary outcomes included major depressive disorder as measured by the Patient Hea

83 erated in this study involving patients with major depressive disorder associated with subthreshold h

84 n (defined as no longer being diagnosed with major depressive disorder at 12 months follow-up), in th

85 ) associated with experiencing an episode of major depressive disorder before the first magnetic reso

86 Alzheimer's disease, schizophrenia, autism, major depressive disorder, body mass index, intracranial

87 -based morphometric studies of patients with major depressive disorder, both antidepressant responder

88 t medication for treatment-naive adults with major depressive disorder by defining a neuroimaging bio

89 Predicting treatment response for major depressive disorder can provide a tremendous benef

90 Parents with recurrent major depressive disorder, co-parents, and offspring (ag

91 Patients with major depressive disorder completed two rtfMRI-nf sessio

92 NRG3 class I was increased in bipolar and major depressive disorder, consistent with observations

93 tidepressant efficacy in adult patients with major depressive disorder experiencing persistent sympto

94 ippocampus and this system is underactive in major depressive disorder, facilitating the development

95 ive serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve

96 l Manual of Mental Disorders IV criteria for major depressive disorder from primary care and psycholo

97 The study included 188 patients with major depressive disorder from the National Institute of

98 ged >/=58 years) meeting DSM-IV criteria for major depressive disorder from the Ralph H Johnson Veter

99 tive trials of CRF1 receptor antagonists for major depressive disorder, generalized anxiety disorder,

100 Major depressive disorder has been associated with dysre

101 A number of randomized controlled trials in major depressive disorder have employed a sequential mod

102 Many patients with major depressive disorder have treatment-resistant depre

103 sants versus nonpharmacologic treatments for major depressive disorder in adults.

104 to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents.

105 of mice susceptible to chronic stress and of major depressive disorder in humans.

106 bipolar disorder may differ from those with major depressive disorder in neural mechanisms underlyin

107 vel and promising candidate for treatment of major depressive disorder in patients who have an inadeq

108 ative care model for treatment of adolescent major depressive disorder in primary care settings.

109 acy for schizophrenia, bipolar disorder, and major depressive disorder in the discovery as well as in

110 are and rank antidepressants and placebo for major depressive disorder in young people.

111 Major depressive disorder is among the most commonly dia

112 edicted that brain activity in patients with major depressive disorder is associated with an overacti

113 Major depressive disorder is associated with disturbed c

114 Major depressive disorder is associated with raised peri

115 Major depressive disorder is characterized by reduced re

116 Major depressive disorder is increasingly recognized to

117 Major depressive disorder is often linked to stress.

118 Major depressive disorder is one of the most common ment

119 The neuroinflammatory hypothesis of major depressive disorder is supported by several main f

120 (generation 2) had 2-fold increased risk for major depressive disorder (MDD) (hazard ratio [HR], 2.02

121 Less than one-third of patients with major depressive disorder (MDD) achieve remission with t

122 Converging evidence suggests that major depressive disorder (MDD) affects multiple large-s

123 Thirty-three outpatients with major depressive disorder (MDD) and 20 matched controls

124 Major depressive disorder (MDD) and alcohol dependence (

125 We found increased prevalence of major depressive disorder (MDD) and anxiety disorders ov

126 bipolar disorder (BD), schizophrenia (SCZ), major depressive disorder (MDD) and autism spectrum diso

127 sequence underlying the association between major depressive disorder (MDD) and cardio-metabolic dis

128 tergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls.

129 Emotional brain activation is altered in major depressive disorder (MDD) and implicated in treatm

130 Furthermore, p11 has been implicated in major depressive disorder (MDD) and in the actions of an

131 Major depressive disorder (MDD) and nicotine dependence

132 The association between major depressive disorder (MDD) and obesity may stem fro

133 Major depressive disorder (MDD) and other mood disorders

134 We also observed a shared genetic basis for major depressive disorder (MDD) and schizophrenia (P < 1

135 Major depressive disorder (MDD) and schizophrenia (SZ) a

136 It is strongly associated with major depressive disorder (MDD) and several other psychi

137 In major depressive disorder (MDD) appetitive motivation is

138 demonstrates that individuals diagnosed with major depressive disorder (MDD) are characterized by sho

139 ence suggests that long-term trajectories of major depressive disorder (MDD) are heterogeneous.

140 The molecular mechanisms underlying major depressive disorder (MDD) are largely unknown.

141 Evidence-based treatments for major depressive disorder (MDD) are not very successful

142 The neuro-anatomical substrates of major depressive disorder (MDD) are still not well under

143 e associated with an increased likelihood of major depressive disorder (MDD) as well as suicidal thou

144 We used polygenic risk scores for major depressive disorder (MDD) calculated from the resu

145 Response to antidepressant treatment in major depressive disorder (MDD) cannot be predicted curr

146 udy investigated intrinsic brain networks in major depressive disorder (MDD) during a depressive epis

147 ntributes to or underlies the development of major depressive disorder (MDD) during this sensitive pe

148 logram (EEG) characteristics associated with major depressive disorder (MDD) has accumulated diverse

149 rostructure of white matter in patients with major depressive disorder (MDD) has been demonstrated to

150 known antidepressant activity, their use in major depressive disorder (MDD) has been greatly limited

151 Research into the pathophysiology of major depressive disorder (MDD) has focused largely on i

152 Although major depressive disorder (MDD) has low heritability, a

153 The search for genetic variants underlying major depressive disorder (MDD) has not yet provided fir

154 Current treatments for major depressive disorder (MDD) have a time lag and are

155 Schizophrenia, bipolar disorder and major depressive disorder (MDD) have all been associated

156 The clinical diagnosis and symptoms of major depressive disorder (MDD) have been closely associ

157 f altered grey and white matter structure in Major Depressive Disorder (MDD) have been inconsistent.

158 Patients with major depressive disorder (MDD) have clinically relevant

159 Studies of patients with major depressive disorder (MDD) have consistently report

160 Both bipolar disorder (BD) and major depressive disorder (MDD) have high morbidity and

161 Genome-wide association studies (GWASs) of major depressive disorder (MDD) have identified few sign

162 ic adenosine monophosphate (cAMP) cascade in major depressive disorder (MDD) have noted that the cAMP

163 The syndromic heterogeneity of major depressive disorder (MDD) hinders understanding of

164 Heterogeneity of major depressive disorder (MDD) illness course complicat

165 tic resonance imaging research suggests that major depressive disorder (MDD) in both adults and adole

166 Major depressive disorder (MDD) in general, and anxious-

167 Major depressive disorder (MDD) in the elderly is a risk

168 investigated NAc structural abnormalities in major depressive disorder (MDD) in two cohorts.

169 dies of illness progression in patients with major depressive disorder (MDD) indicate that the onset

170 Major depressive disorder (MDD) is a complex and heterog

171 Major depressive disorder (MDD) is a debilitating and wi

172 Major depressive disorder (MDD) is a debilitating condit

173 Major depressive disorder (MDD) is a debilitating mental

174 Major depressive disorder (MDD) is a disabling mood diso

175 Major depressive disorder (MDD) is a leading cause of di

176 Major depressive disorder (MDD) is a prevalent psychiatr

177 Major depressive disorder (MDD) is a recurring psychiatr

178 Major depressive disorder (MDD) is a substantial burden

179 Major depressive disorder (MDD) is among the leading cau

180 and non-human animal research suggests that Major Depressive Disorder (MDD) is associated with abnor

181 Major depressive disorder (MDD) is associated with defic

182 A chronic course of major depressive disorder (MDD) is associated with profo

183 Major depressive disorder (MDD) is associated with reduc

184 Major depressive disorder (MDD) is characterized by abno

185 Major depressive disorder (MDD) is clinically, and likel

186 Major depressive disorder (MDD) is common among children

187 Early-onset major depressive disorder (MDD) is common in individuals

188 owever, evidence for leptin dysregulation in major depressive disorder (MDD) is conflicting.

189 Its relationship with major depressive disorder (MDD) is of particular importa

190 Major depressive disorder (MDD) is predicted to be the s

191 Major depressive disorder (MDD) is prevalent among patie

192 Major depressive disorder (MDD) is the second largest ca

193 nostic criteria for mood disorders including major depressive disorder (MDD) largely ignore biologica

194 The heterogeneity of genetic effects on major depressive disorder (MDD) may be partly attributab

195 Limited successes of gene finding for major depressive disorder (MDD) may be partly due to phe

196 Major depressive disorder (MDD) often emerges during ado

197 e impact of daily stressors and a history of major depressive disorder (MDD) on inflammatory response

198 subjects who met DSM-IV criteria for either major depressive disorder (MDD) or bipolar disorder I/II

199 e (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks.

200 lia density to decrease in areas critical to Major Depressive Disorder (MDD) pathophysiology at the t

201 Major depressive disorder (MDD) patients display a commo

202 erations of brain functional connectivity in major depressive disorder (MDD) patients with suicidal i

203 leus accumbens (NAcc) have been reported for major depressive disorder (MDD) patients.

204 ecrease depressive symptoms in a subgroup of major depressive disorder (MDD) patients.

205 structural brain alterations associated with major depressive disorder (MDD) remains unresolved.

206 rocessing are two primary characteristics of major depressive disorder (MDD) that may persist after r

207 Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently a

208 rder (BDD) versus depressed individuals with major depressive disorder (MDD) versus healthy control s

209 IL-18 and mu-opioid receptor availability in major depressive disorder (MDD) volunteers.

210 ntidepressant medication in outpatients with major depressive disorder (MDD) was examined in a 3-site

211 Patients with remitted major depressive disorder (MDD) were previously found to

212 ate receptor antagonist ketamine can improve major depressive disorder (MDD) within hours.

213 ty in 50 patients with FEP, 50 patients with major depressive disorder (MDD), 50 patients with post-t

214 Human major depressive disorder (MDD), along with related mood

215 pheral inflammation is often associated with major depressive disorder (MDD), and immunological bioma

216 te that the glutamate system is disrupted in major depressive disorder (MDD), and recent clinical res

217 gories-posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and the anxiety disorde

218 ts with major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD),

219 ltiple neuropsychiatric disorders, including major depressive disorder (MDD), bipolar disorder, anxie

220 91 individuals with a principal diagnosis of major depressive disorder (MDD), bipolar disorder, or sc

221 Millions of patients suffer from major depressive disorder (MDD), but many do not respond

222 5 findings in stress disorders, particularly major depressive disorder (MDD), highlighting insights f

223 compared the relative importance of atypical major depressive disorder (MDD), nonatypical MDD, and dy

224 rong evidence supporting the heritability of major depressive disorder (MDD), previous genome-wide st

225 Major depressive disorder (MDD), schizophrenia (SCZ) and

226 rTMS) have been investigated as treatment of major depressive disorder (MDD), their comparative effic

227 moderate, well-demonstrated heritability of major depressive disorder (MDD), there has been limited

228 disorders, such as bipolar disorder (BD) and major depressive disorder (MDD).

229 to antidepressant efficacy in patients with major depressive disorder (MDD).

230 eration antidepressants for the treatment of major depressive disorder (MDD).

231 ention is one of the most common symptoms in major depressive disorder (MDD).

232 o omega-3 (n-3) fatty acids in subjects with major depressive disorder (MDD).

233 icated in stress-related illnesses including major depressive disorder (MDD).

234 treatment of psychiatric diseases including major depressive disorder (MDD).

235 niopyridine neurogenic compound for treating major depressive disorder (MDD).

236 ted evidence for its efficacy in nonseasonal major depressive disorder (MDD).

237 ies as a component of the pathophysiology of major depressive disorder (MDD).

238 t a potential role in the pathophysiology of major depressive disorder (MDD).

239 have yet to be reported in individuals with major depressive disorder (MDD).

240 icated the serotonin 1A (5-HT1A) receptor in major depressive disorder (MDD).

241 brain alteration in patients diagnosed with major depressive disorder (MDD).

242 15 mRNA reduction in NAc of individuals with major depressive disorder (MDD).

243 ants (ADs) are the most common treatment for major depressive disorder (MDD).

244 f mood-related disorders such as anxiety and major depressive disorder (MDD).

245 ing evidence supports a role for dopamine in major depressive disorder (MDD).

246 al neural network functional connectivity in major depressive disorder (MDD).

247 have been observed frequently in adults with major depressive disorder (MDD); however, results have b

248 At baseline, 4853 veterans (19%) with major depressive disorder (MDD; International Classifica

249 (r g = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07)

250 (r g = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07)

251 to develop and test treatment predictors for major depressive disorders (MDDs), whereas imaging marke

252 ctory impairments in patients suffering from major depressive disorders (MDDs), yet the underlying ph

253 nosed with either bipolar disorder (N=34) or major depressive disorder (N=69).

254 nosed with either bipolar disorder (N=34) or major depressive disorder (N=69).

255 e of 225 adults from five diagnostic groups (major depressive disorder, N=32; bipolar disorder, N=50;

256 it hyperactivity disorder, bipolar disorder, major depressive disorder, neuroticism, schizophrenia an

257 nts and young adults with moderate to severe major depressive disorder, none of whom were being treat

258 were also found between any 12-month DUD and major depressive disorder (odds ratio [OR], 1.3; 95% CI,

259 imensions of cognitive control in women with major depressive disorder or bipolar disorder in compari

260 Dec 13, 2001, and Jan 31, 2014, with either major depressive disorder or bipolar disorder who were e

261 In patients with major depressive disorder or bipolar disorder, abnormali

262 day 3 (D3) were measured in 51 patients with major depressive disorder or bipolar disorder.

263 e association studies that focused on either major depressive disorder or depressive symptoms with mo

264 ism but not schizophrenia, bipolar disorder, major depressive disorder, or attention-deficit/hyperact

265 sive symptoms within 24 hours in a subset of major depressive disorder patients.

266 rs, including obsessive-compulsive disorder, major depressive disorder, posttraumatic stress disorder

267 At least 15% of cases of major depressive disorder remain refractory to treatment

268 Not all patients with major depressive disorder respond to adequate pharmacolo

269 a (SCZ), bipolar disorder (BD) and recurrent major depressive disorder (rMDD) are common psychiatric

270 Remitted patients with major depressive disorder (rMDD) often report more fluct

271 A total of 154 medication-free patients with major depressive disorder seeking treatment at two unive

272 re common but variable diagnostic markers in major depressive disorder: some depressed individuals ma

273 non-psychiatric controls (CON, N=29), DSM-IV major depressive disorder suicides (MDD-S, N=21) and MDD

274 armacologic Treatment of Adult Patients with Major Depressive Disorder." The evidence review done for

275 of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to of

276 dy developed bipolar disorder and those with major depressive disorder, these neuroimaging findings m

277 come of 25 patients with treatment-resistant major depressive disorder (TRD) who participated in an I

278 Among a predominantly male population with major depressive disorder unresponsive to antidepressant

279 ize brain network dysfunctions that underlie major depressive disorder using brain oscillation measur

280 The SNP-based heritability of major depressive disorder was 0.21 (SE = 0.02), the SNP-

281 Prevalence of major depressive disorder was 2.2% (95% UI 1.5-2.8) in C

282 Prevalence of major depressive disorder was 3.3% (2.3-4.1) in Chinese

283 Major depressive disorder was diagnosed in 22 (4%) parti

284 rmacotherapy in the treatment of adults with major depressive disorder were considered for inclusion

285 Forty-nine individuals diagnosed with major depressive disorder were enrolled with intent to t

286 hotropic medication and presence of comorbid major depressive disorder were important moderators that

287 Two patient groups with acute major depressive disorder were included.

288 aged 11-17 years) with a diagnosis of DSM IV major depressive disorder were randomly assigned (1:1:1)

289 Adult outpatients with major depressive disorder were randomly assigned to open

290 METHOD: Adult outpatients with major depressive disorder were randomly assigned to open

291 althy, aged 18 to 65 years, met criteria for major depressive disorder, were free of psychotropic med

292 symptoms, but who did not meet criteria for major depressive disorder, were randomly assigned (1:1),

293 in cholinergic signaling are associated with major depressive disorder, whereas pre-clinical studies

294 Bipolar disorder is often misdiagnosed as major depressive disorder, which leads to inadequate tre

295 In participants with major depressive disorder who are trained to upregulate

296 t for the large portion of older adults with major depressive disorder who do not respond to first-li

297 Patients meeting DSM-IV-TR criteria for major depressive disorder who presented with two or thre

298 atal circuitry and behavior in patients with major depressive disorder will also be presented.

299 ted the efficacy and safety of lurasidone in major depressive disorder with mixed features.

300 euro Imaging Genetics through Meta-Analysis) Major Depressive Disorder Working Group on cortical stru